stockrow
Friday 6 November 2026
Export RNXT’s income statement to Excel — free account
RenovoRx, Inc.
RNXT Healthcare Biotechnology
RenovoRx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 million, up 2,511.6% from fiscal 2024.
- Revenue
- +300.8%
- EPS
- 0.00%
- Free cash flow
- −12.7%
Quarter to September 2026, against a year earlier
1.14
0.05
−4.20%
Follow RNXT
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | 0 | 1 | 3 | +2,511.6% | 4 | 11 | 34 | +210.2% | |
| Gross margin, % | — | — | — | — | — | 0.00 | 0.00 | — | 100.00 | 70.88 | 84.04 | +70.9 pt | ||||||
| EBT | — | — | — | (4) | (4) | (6) | (10) | (10) | (9) | (11) | (13) | +19.5% | ||||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (20,497.67) | (994.48) | (469.02) | (994.5) pt | ||||||
| Net income | — | 0 | — | (4) | (4) | (6) | (10) | (10) | (9) | (11) | (13) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.06 | n/m | |||||
| Earnings | — | — | — | (1.76) | (1.72) | (1.21) | (1.09) | (0.99) | (0.40) | (0.32) | (0.31) | (24.8%) | ||||||
| Cash flow | — | — | — | (1.54) | (1.59) | (1.13) | (0.97) | (1.00) | (0.41) | (0.31) | (0.25) | (23.4%) | ||||||
| Capex | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | (1.54) | (1.59) | (1.14) | (0.97) | (1.00) | (0.41) | (0.31) | (0.25) | (23.4%) | ||||||
| Book value | — | — | — | (5.02) | (6.62) | 2.94 | 0.68 | (0.29) | 0.20 | 0.15 | 0.19 | n/m | ||||||
| Shares, m | — | — | — | 2 | 2 | 5 | 9 | 10 | 22 | 35 | 42 | +59.1% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | — | — | — | 0.00 | 26.43 | 19.79 | 13.2 | ||||||
| P/B | — | — | — | — | — | — | — | — | 6.42 | 5.47 | 5.92 | 5.9 | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | 0.00 | 24.45 | 17.77 | 12.2 | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | (2.88) | (2.50) | (4.04) | (2.7) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (3) | (4) | (6) | (9) | (10) | (9) | (11) | (12) | +21.9% | |||||
| Capex | — | — | — | — | — | 0 | — | — | 0 | 0 | 0 | (39.6%) | ||||||
| Free cash flow | — | — | — | (3) | (4) | (6) | (9) | (10) | (9) | (11) | (12) | +21.9% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | 1 | (2) | 15 | 6 | 0 | 6 | 6 | 10 | +26.3% | |||||
| Net debt | — | — | — | 10 | 1 | (15) | (6) | (1) | (7) | (7) | (10) | n/m | ||||||
| Shareholders’ equity | — | — | — | (11) | (15) | 15 | 6 | (3) | 4 | 5 | 9 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | (338.24) | (181.55) | (69.49) | (83.98) | (234.38) | (183.93) | (137.77) | (110.14) | +200.5 pt | |||||
| ROIC | — | — | — | 0.00 | 0.00 | (2,257.56) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | 30.01 | 29.69 | (1,825.11) | (91.94) | (646.98) | (1,192.69) | (225.62) | (149.98) | (255.6) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 8 | 6 | 9 | 8 | 10 | 17 | — | +16.3% | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026
RenovoRx, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| XLO Xilio Therapeutics, Inc. | $55.9M | — (loss-making) | — (loss-making) | +131.22% (above 0%: growing) | n/m | −26.23% (below 0%: shrinking) | 100.00% | (18.68%) | Compare |
| CRBP Corbus Pharmaceuticals Holdings, Inc. | $55.3M | — (loss-making) | — (loss-making) | −92.09% (below 0%: shrinking) | n/m | −78.52% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| BOLD Boundless Bio, Inc. | $54.8M | — (loss-making) | — | — | n/m | −76.90% (below 0%: shrinking) | — | 0.00% | Compare |
| RNXT RenovoRx, Inc. | $53.7M | — (loss-making) | — (loss-making) | +300.75% (above 0%: growing) | n/m | −12.69% (below 0%: shrinking) | 82.36% | (303.56%) | |
| HRTX Heron Therapeutics, Inc. | $53.2M | — (loss-making) | — (loss-making) | +1.25% (above 0%: growing) | n/m | +78.75% (above 0%: growing) | 69.28% | (5.43%) | Compare |
| VRCA Verrica Pharmaceuticals Inc. | $53.1M | — (loss-making) | — (loss-making) | −53.85% (below 0%: shrinking) | n/m | +7.63% (above 0%: growing) | 85.02% | (223.42%) | Compare |
| RNTX Rein Therapeutics Inc. | $52.8M | — (loss-making) | — | — | n/m | −34.62% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ALPS Alps Group Inc. | $52.3M | — (loss-making) | — | — | n/m | −26.48% (below 0%: shrinking) | — | 0.00% | Compare |
| ELOX Senesco Technologies Inc. | $51.7M | — (loss-making) | — | — | n/m | −144.34% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| Median of peers | $53.1M | — | — | −26.30% | — | −30.55% | 77.15% | 0.00% |
Pay and ownership Proxy statement filed 30 April 2026
Ownership
Directors and executive officers, together
9.40%
Orin Hirschman
9.80%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement